



Appendix: Supplemental Figures and Tables



Supplemental Figure 1. Sampling criteria to arrive at final cohorts.

Supplemental Figure 2. Proposed model performance in comparison to pooled cohort Equations (PCE) and Framingham risk score (FRS) as measured by receiver operating characteristic and precision-recall curves for 1-year (a) and 5-year (b) IHD risk prediction. Shaded areas correspond to 95% confidence intervals. In figure legend area under receiver operating characteristic (AUROC) and precision-recall (AUCPR) curves are shown. Below, *P* values for pair-wise comparisons between models are reported. Confidence intervals (CI) and *P* values were obtained using the DeLong method for AUROC and the bootstrap method for AUCPR.



Supplemental Figure 3. Segmentation model performance. CV : coefficient of variation, HU: Hounsfield Unit, CSA: cross-sectional area. Center line represents median, box limits upper and lower quartiles, whiskers 1.5x interquartile range, and points outliers.

Model	Hyperparameters tested	Best Validation AUROC	
		1y	5y
Segmentation only Imaging only	C: {0.01, 0.1, 0.5, 1.0, 5**, 10}	.6757	.6907
Selected configuration	Batch size 8		
	Learning rate {1e-5*, 1e-6**}		
	Adam optimizer	.7331	.7969
	Max epochs {10*, 30**}		
Training only final layer	Cross Entropy Loss		
	Batch size 8		
	Learning rate {1e-4, 1e-5, 1e-6}		
	Adam optimizer	.5656	.6523
	Max epochs 15		
Image augmentations	Cross Entropy Loss		
	Batch size 8		
	Learning rate {1e-3, 1e-4, 1e-5, 1e-6}		
	Adam optimizer		
	Max Epochs 20	.7089	.7867
	Cross Entropy Loss		
	Rotations of up to 3° and pixel shifting of up to 5 pixels during training		
Focal loss	Batch size 8		
	Learning rate {1e-4, 1e-5, 1e-6}		
	Adam optimizer	.7275	.7879
	Max epochs 20		
	Focal loss (gamma:{2,3,4,5,10} alpha:[.01,.99],[0.05,0.95])		
	Augmentations {Yes/No}		
Clinical only	colsample_bytree:{2, 4**, .6, .8, 1*}		
	gamma:{1, .5**, 1, 10*}		
	max_depth: {1, 2, 3, 4, 5**, 6}	.7851	.7935
	min_child_weight: {1, .5**, 1*}		
	subsample: {.5*, .75**, 1}		
	scale_pos_weight:{1**, 5, 10, 15, 20}		
PCE + segmentation	colsample_bytree:{2**, .4, .6, .8, 1}		
	gamma:{1, .5, 1, 10**}		
	max_depth: {1, 2, 3*, 4, 5**, 6}	.7427	.7262
	min_child_weight: {1*, .5, 1**}		
	subsample: {.5**, .75, 1*}		
Imaging + Clinical Fusion	C: {0.1, 0.5, 1.0, 5**, 10, 20, 30, 50, 100*, 500, 1000}	.9737	.9751
Imaging + Clinical + Segmentation Fusion	C: {0.1, 0.5, 1.0, 5**, 10, 20, 30, 50, 100*, 500, 1000**}	.9777	.9805

Supplemental Table 1. Validation performance of alternative training schemes and hyperparameters of predictive models. *, **: hyperparameters selected for 1-year and 5-year IHD prediction, respectively.

Supplemental Table 2. Variables captured from the electronic medical record and used as covariates of Clinical only model. (See attached file).

Variable	1-year follow-up								5-year follow-up															
	Train				Test				Train				Test											
	non-IHD (n=6292)		IHD (n=287)		non-IHD (n=1547)		IHD (n=71)		non-IHD (n=1051)		IHD (n=357)		non-IHD (n=265)		IHD (n=89)									
	%	/ Mean (SD)	missing	%	/ Mean (SD)	missing	%	/ Mean (SD)	missing	%	/ Mean (SD)	missing	%	/ Mean (SD)	missing									
Age	51.2	(17.1)	0	63.9	(14.3)	0	50.9	(16.5)	0	65.8	(15.4)	0	51.6	(16.4)	0	63.9	(15.3)	0	50.6	(16.9)	0	62.7	(13.8)	0
Male Sex	39.5		0	51.2		0	41.8		0	52.1		0	37.6		0	51.5		0	32.8		0	42.7		0
Smoking	6.2		177	6.3		1	6.6		59	1.45		2	5.7		32	7.1		3	5.0		7	3.4		0
Race/Ethnicity			0			0			0			0			0			0			0			0
Non-Hispanic White	48.0			43.2			49.5			50.7			52.9			45.6			51.4			41.7		
Non-Hispanic Black	3.9			2.8			4.0			2.8			3.1			2.4			3.6			4.2		
Hispanic	21.5			20.9			18.8			21.1			17.8			20.0			21.3			26.4		
Asian	16.2			20.9			15.9			15.5			15.1			19.6			14.5			19.4		
Other/Unknown	10.3			12.2			11.8			9.9			11.1			12.6			9.2			8.3		
Treated for hypertension	25.4		0	49.5		0	23.6		0	52.1		0	28.4		0	51.0		0	25.7		0	49.4		0
Diabetes diagnosis	13.9		0	28.2		0	12.9		0	16.9		0	12.4		0	25.8		0	13.6		0	27.0		0
HDL Cholesterol [mg/dL]	56.9	(20.3)	5113	57.3	(22.7)	226	56.4	(20.2)	1244	57.6	(14.2)	57	56.9	(23.4)	840	55.8	(19.5)	269	55.3	(17.9)	211	61.8	(24.2)	69
Total Cholesterol [mg/dL]	183.1	(45.7)	5039	173.9	(48.1)	224	189.0	(47.5)	1238	178.4	(49.4)	53	187.4	(45.4)	825	177.2	(46.9)	262	177.7	(40.9)	209	184.7	(41.4)	69
Systolic Blood Pressure [mmHg]	124.3	(18.0)	124	129.7	(20.9)	8	124.2	(17.9)	25	128.8	(18.5)	4	123.6	(18.1)	33	128.7	(21)	8	123.8	(17.1)	6	131.3	(20.4)	6
VAT/SAT ratio	.68	(1.6)	0	.86	(.7)	0	.66	(.7)	0	.85	(.6)	0	.63	(.6)	0	.87	(.7)	0	.62	(.5)	0	.80	(.6)	0
Muscle density [HU]	43.9	(9.6)	0	38.2	(9.1)	0	43.7	(9.6)	0	37.7	(7.9)	0	44.0	(9.1)	0	38.7	(8.9)	0	44.3	(9.2)	0	37.4	(8.8)	0

Supplemental Table 3. Distribution of demographic variables across the study population. Features relevant to pooled cohort equations risk assessment, as well as body composition metrics derived from segmentation are also included.

Model	1-year IHD risk				5-year IHD risk			
	Sensitivity [%]	Specificity [%]	PPV [%]	NPV [%]	Sensitivity [%]	Specificity [%]	PPV [%]	NPV [%]
PCE ($\geq 7.5\%$ threshold)	67.6	72.3	10.1	98.0	56.2	75.5	10.1	83.7
PCE ($\geq 20\%$ threshold)	35.2	87.8	11.7	96.7	31.5	87.5	11.7	79.2
Segmentation only	80.3	53.0	7.3	98.3	78.7	62.6	41.4	89.7
Clinical Only	69.0	71.6	10.0	98.1	84.3	70.6	49.0	93.0
Imaging Only	70.4	66.8	8.9	98.0	78.7	71.3	47.9	90.9
Imaging + Clinical Fusion	71.8	71.6	10.4	98.2	83.1	76.2	54.0	93.1

Supplemental Table 4. Performance of proposed classification models using Youden's index as threshold, compared to two clinically relevant thresholds for pooled cohort equations (PCE).

Supplemental Table 5. Performance of proposed prediction models, along with Framingham Risk Score (FRS) and Pooled Cohort Equations (PCE) in different subpopulations of the test set. y/o: years old. (See attached file).